I recall that one. Thx for posing it. My quote from Nasrat was also mentioned in Q4 cc verbatim.
Great to see the CNS expansion, I’d like to see a shift away from here as well. They have done and will only continue to do better with the CNS market. I just worry about the inherent risk of CNS drugs in general.